Literature DB >> 23345543

Lymph node ratio predicts recurrence in papillary thyroid cancer.

David F Schneider1, Haggi Mazeh, Herbert Chen, Rebecca S Sippel.   

Abstract

BACKGROUND: Lymph node metastasis occurs in 20%-50% of patients presenting for initial treatment of papillary thyroid cancer (PTC). The significance of lymph node metastases remains controversial, and the aim of this study is to determine how the lymph node ratio (LNR) may predict the likelihood of disease recurrence.
METHODS: We conducted a retrospective review of patients undergoing total thyroidectomy for PTC at our institution from 2005 to 2010. A total LNR (positive nodes to total nodes) and central lymph node ratio (cLNR) was calculated. Regression was used to determine a threshold LNR that best predicted recurrence. Multivariate logistic regression then determined the influence of LNR on recurrence while accounting for other known predictors of recurrence. Kaplan-Meier analysis and the log-rank test were used to compare differences in disease-free survival.
RESULTS: Of the 217 patients undergoing total thyroidectomy for PTC, 69 patients had concomitant neck dissections. Sixteen (23.2%) patients developed disease recurrence. When disease-free survival functions were compared, we found that patients with a total LNR ≥0.7 (p < .01) or a cLNR ≥0.86 (p = .04) had significantly worse disease-free survival rates than patients with ratios below these threshold values. Considering other known predictors of recurrence, we found that LNR was significantly associated with recurrence (odds ratio: 19.5, 95% confidence interval: 4.1-22.9; p < .01).
CONCLUSIONS: Elevated total LNR and cLNR are strongly associated with recurrence of PTC after initial operation. LNR in PTC is a tool that can be used to determine the likelihood of the patient developing recurrent disease and inform postoperative follow-up.

Entities:  

Mesh:

Year:  2013        PMID: 23345543      PMCID: PMC3579599          DOI: 10.1634/theoncologist.2012-0240

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  38 in total

1.  Colon cancer clinical practice guidelines in oncology.

Authors:  Paul F Engstrom; Al B Benson; Yi-Jen Chen; Michael A Choti; Raza A Dilawari; Charles A Enke; Marwan G Fakih; Charles Fuchs; Krystyna Kiel; James A Knol; Lucille A Leong; Kirk A Ludwig; Edward W Martin; Sujata Rao; M Wasif Saif; Leonard Saltz; John M Skibber; Alan P Venook; Timothy J Yeatman
Journal:  J Natl Compr Canc Netw       Date:  2005-07       Impact factor: 11.908

2.  Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study.

Authors:  Catharina Ihre Lundgren; Per Hall; Paul W Dickman; Jan Zedenius
Journal:  Cancer       Date:  2006-02-01       Impact factor: 6.860

3.  An expanded view of risk-group definition in differentiated thyroid carcinoma.

Authors:  B Cady; R Rossi
Journal:  Surgery       Date:  1988-12       Impact factor: 3.982

4.  Prospective multicenter study of thyroiscarcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group.

Authors:  S I Sherman; J D Brierley; M Sperling; K B Ain; S T Bigos; D S Cooper; B R Haugen; M Ho; I Klein; P W Ladenson; J Robbins; D S Ross; B Specker; T Taylor; H R Maxon
Journal:  Cancer       Date:  1998-09-01       Impact factor: 6.860

5.  Improved survival of patients with papillary thyroid cancer after surgical microdissection.

Authors:  L E Tisell; B Nilsson; J Mölne; G Hansson; M Fjälling; S Jansson; U Wingren
Journal:  World J Surg       Date:  1996-09       Impact factor: 3.352

6.  Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis.

Authors:  Sophie Leboulleux; Carole Rubino; Eric Baudin; Bernard Caillou; Dana M Hartl; Jean-Michel Bidart; Jean-Paul Travagli; Martin Schlumberger
Journal:  J Clin Endocrinol Metab       Date:  2005-07-19       Impact factor: 5.958

7.  Impact of lymph node metastasis in differentiated carcinoma of the thyroid: a matched-pair analysis.

Authors:  C J Hughes; A R Shaha; J P Shah; T R Loree
Journal:  Head Neck       Date:  1996 Mar-Apr       Impact factor: 3.147

8.  Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system.

Authors:  I D Hay; C S Grant; W F Taylor; W M McConahey
Journal:  Surgery       Date:  1987-12       Impact factor: 3.982

9.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.

Authors:  E L Mazzaferri; S M Jhiang
Journal:  Am J Med       Date:  1994-11       Impact factor: 4.965

10.  Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer.

Authors:  G F Scheumann; O Gimm; G Wegener; H Hundeshagen; H Dralle
Journal:  World J Surg       Date:  1994 Jul-Aug       Impact factor: 3.352

View more
  23 in total

1.  Quantification of lymph nodes in the central compartment of the neck: a cadaveric study.

Authors:  Enyinnaya Ofo; Selvam Thavaraj; Daron Cope; James Barr; Karan Kapoor; Jean-Pierre Jeannon; Richard Oakley; Claire Lock; Edward Odell; Ricard Simo
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-11-20       Impact factor: 2.503

2.  Markedly elevated thyroglobulin levels in the preoperative thyroidectomy patient correlates with metastatic burden.

Authors:  Sarah C Oltmann; Glen Leverson; Suzy Hsiu-I Lin; David F Schneider; Herbert Chen; Rebecca S Sippel
Journal:  J Surg Res       Date:  2013-12-18       Impact factor: 2.192

3.  Back so soon? Is early recurrence of papillary thyroid cancer really just persistent disease?

Authors:  Maria F Bates; Marcos R Lamas; Reese W Randle; Kristin L Long; Susan C Pitt; David F Schneider; Rebecca S Sippel
Journal:  Surgery       Date:  2017-11-08       Impact factor: 3.982

4.  Pediatric papillary thyroid carcinoma: outcomes and survival predictors in 2504 surgical patients.

Authors:  Samuel Golpanian; Eduardo A Perez; Jun Tashiro; John I Lew; Juan E Sola; Anthony R Hogan
Journal:  Pediatr Surg Int       Date:  2015-12-30       Impact factor: 1.827

Review 5.  New developments in the diagnosis and treatment of thyroid cancer.

Authors:  David F Schneider; Herbert Chen
Journal:  CA Cancer J Clin       Date:  2013-06-24       Impact factor: 508.702

6.  Lymph node metastases do not impact survival in follicular variant papillary thyroid cancer.

Authors:  David F Schneider; Dawn Elfenbein; Ricardo V Lloyd; Herbert Chen; Rebecca S Sippel
Journal:  Ann Surg Oncol       Date:  2014-08-05       Impact factor: 5.344

7.  Remnant uptake as a postoperative oncologic quality indicator.

Authors:  David F Schneider; Kristin A Ojomo; Herbert Chen; Rebecca S Sippel
Journal:  Thyroid       Date:  2013-07-17       Impact factor: 6.568

8.  Patient Report of Recurrent and Persistent Thyroid Cancer.

Authors:  Maria Papaleontiou; Josh M Evron; Nazanene H Esfandiari; David Reyes-Gastelum; Kevin C Ward; Ann S Hamilton; Francis Worden; Megan R Haymart
Journal:  Thyroid       Date:  2020-04-16       Impact factor: 6.568

9.  Difficulties in deciding whether to ablate patients with putatively "low-intermediate-risk" differentiated thyroid carcinoma: do guidelines mainly apply in the centres that produce them? Results of a retrospective, two-centre quality assurance study.

Authors:  Savvas Frangos; Ioannis P Iakovou; Robert J Marlowe; Nicolaos Eftychiou; Loukia Patsali; Anna Vanezi; Androulla Savva; Vassilis Mpalaris; Evanthia I Giannoula
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-08-01       Impact factor: 9.236

Review 10.  Ethanol Ablation of Neck Metastases from Differentiated Thyroid Carcinoma.

Authors:  Ricardo Paz-Fumagalli; Xi Li; Robert C Smallridge
Journal:  Semin Intervent Radiol       Date:  2019-12-02       Impact factor: 1.513

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.